Cosmo Pharmaceuticals released topline Phase III results for clascoterone 5% topical solution in androgenetic alopecia, reporting a combined 252% relative improvement in Target‑Area Hair Count across two trials (SCALP 1 and SCALP 2) that enrolled 1,465 patients. SCALP 2 showed a 539% relative improvement versus vehicle. Investors reacted strongly, sending Cosmo shares up nearly 40% over the week. Cosmo plans peer‑reviewed publication and conference presentations next year; the program could expand use of clascoterone beyond its existing acne indication.